Last checked at 31 Oct 2013 12:45
For immediate release | 31 October 2013 |
Futura Medical plc
("Futura" or "the Company")
Total Voting Rights
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 77,757,484 ordinary shares of 0.2p each, with one voting right per share. There are no shares held in treasury.
The total number of voting rights in the Company is therefore 77,757,484.
The above figure of 77,757,484 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive
| Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
Cenkos Securities plc |
|
Bobbie Hilliam | Tel:+44 (0)20 7397 8900 |
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Fiona Henson / Sophie Cowles | Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com